Legal Update Getting Out Your Message without Getting in Hot Water: HTC Marketing and the Grant Rules by Elizabeth (Issie) Karan Hemophilia Treatment Centers (HTCs) reach out to the Hemophilia Read the full article…
Legal Update State Laws Regulating Pharmacy Reimbursement, ERISA,and the Supreme Court – What Could Rutledge Mean for 340B Covered Entities? by Elizabeth (Issie) Karan On December 10, 2020, in Rutledge Read the full article…
In recent weeks, the Trump Administration released a long-awaited on the Alternative Dispute Resolution (ADR) process in the 340B Drug Discount Program (340B Program).
As part of the Department of Health and Human Services’ (HHS’) “Regulatory Sprint to Coordinated Care,” the Centers for Medicare & Medicaid Services (CMS) and the HHS Office of the Inspector General (OIG) both released final regulations on Friday, November 20, 2020.
HTCs often inquire with the Hemophilia Alliance regarding what is an appropriate “indirect cost rate.”
Under the auspices of 340B Program compliance, manufacturers recently requested extensive data from covered entities related to drugs dispensed through contract pharmacies.
Under the auspices of 340B Program compliance, manufacturers recently requested extensive data from covered entities related to drugs dispensed through contract pharmacies.
In recent weeks, three drug manufacturers have taken unprecedented actions that threaten covered entity participation in the 340B Discount Drug Pricing Program (340B Program).
Legal Update Program Income Rules Still Apply During a Public Health Emergency By Elizabeth 'Issie' Karan The COVID-19 epidemic has placed unprecedented challenges on the U.S. economy and healthcare system. Read the full article…
Legal Update 340B Program Flexibilities During COVID-19 Pandemic By Elizabeth 'Issie' Karan Hemophilia Treatment Centers (HTCs) may benefit from relaxation of 340B Drug Pricing Program policies during the COVID-19 pandemic. Read the full article…
